Fig. 1From: Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomesStudy flow chart. T2DM type 2 diabetes mellitus, CV cardiovascularBack to article page